메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

PRC-Saltillo Expands Global Reach with Launch of Singapore…

SINGAPORE, Oct. 14, 2025 -- PRC-Saltillo, a leading provider of AAC (Augmentative and Alternative Communication) devices and support services, is proud to announce the official launch of its wholly owned subsidiary, PRC Saltillo Singapore Pte. Ltd. As PRC-Saltillo enters its 60th year of operation, this expansion marks a new chapter in its mission to empower voices worldwide. Founded in 1966, PRC-Saltillo has been a pioneering force in the industry and one of the few AAC companies led by speech-language pathologists, ensuring clinical relevance and user-centered design.
- 김갑성 기자
- 2025-10-14 08:00
NABR Comment on IUCN Determination

WASHINGTON, Oct. 14, 2025 -- The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" status determination for long-tailed macaque ("LTM") monkeys (Macaca fascicularis). The latest issuance by the IUCN follows a 2023 petition filed by the National Association for Biomedical Research (NABR) challenging the IUCN status determination. NABR's petition demonstrates that reviews by Hansen et. al., which the IUCN has used as the basis for its status determinations, misrepresent existing scientific da
- 김갑성 기자
- 2025-10-14 06:55
Natural Field Drives Breakthroughs in Co-loading Liposome T…

XIAN, China, Oct. 13, 2025 -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This technology demonstrates strong potential in enhancing the bioavailability, stability, and synergistic effects of active ingredients, opening up new pathways for health support. During this R&D process, Natural Field conducted in-depth exploration into the mechanisms of action and efficacy of co-loading
- 김갑성 기자
- 2025-10-13 23:00
DZYNE Expands Dronebuster® Line with New Vehicle Kits at AU…

Autonomous and Manual Kits deliver mobile, layered counter-drone defense, building on 2,500+ systems fielded in over 50 countries WASHINGTON, Oct. 13, 2025 -- DZYNE Technologies today unveiled its new Dronebuster® Vehicle Kits at the Association of the United States Army (AUSA) Annual Meeting in Washington, D.C. The expansion of the combat-proven Dronebuster® line brings mobile counter-UAS protection to vehicles, convoys, and infrastructure – extending capabilities already trusted by forces in over 50 countries, with more than 2,500 units fielded worldwide. "
- 김갑성 기자
- 2025-10-13 22:00
Visionary Holdings (Nasdaq: GV) Secures Global License f…

TORONTO, Oct. 13, 2025 -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"). The agreement grants GV the worldwide rights to apply Yike's breakthrough stem cell technology, which has demonstrated significant potential in advancing treatments for diabetes and with other regenerativ
- 김갑성 기자
- 2025-10-13 21:40
Complete Genomics announces Gene by Gene as its newe…

BOSTON, Oct. 13, 2025 -- Complete Genomics, a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has added Houston-based Gene by Gene, a leading genetics laboratory, to its Sequencing Service Provider Program. The Complete Genomics Service Provider Program connects its customers to a network of service providers, offering access to high-quality sequencing services using Complete Genomics DNBSEQ™ sequencing platforms. "We're excited about partnering with Complete Genomics, which we believe will contribut
- 김갑성 기자
- 2025-10-13 21:00
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivo…

RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, today announced the enrollment of the first patient in its U.S. pivotal clinical trial evaluating Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization. This milestone represents a significant advancement in NEXTBIOMEDICAL's U.S. regulatory pathway, following FDA approval of its Investigational Device
- 김갑성 기자
- 2025-10-13 21:00
iRegene Therapeutics announced promising NouvNeu00…

CHENGDU, China, Oct. 13, 2025 -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS). Excellent safety and tolerability were observed for up to 15 months post-transplantation, no
- 김갑성 기자
- 2025-10-13 21:00
Waters Launches Charge Detection Mass Spectrometry Te…

Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3 MILFORD, Mass., Oct. 13, 2025 -- Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS)
- 김갑성 기자
- 2025-10-13 20:36
Thousand Oaks Biologics Shanghai ADC Site receives EU QP…

SHANGHAI, Oct. 13, 2025 -- Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person (QP) and formally received a QP Declaration. This milestone certifies that the company's quality management system and commercial production capability in the field of antibody-drug conjugates (ADCs) comply with EU Good Manufacturing Practice (GMP) standards, positioning Thousand Oaks Biologics Shanghai as one of the few CDMOs in China offering end-to-end international ADC services. The five-day on-site audit to
- 김갑성 기자
- 2025-10-13 20:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분